Blood
Articles in this Issue
Artificial intelligence predicts genetic network disruptions to overcome CAR-T resistance in Mantle Cell Lymphoma
Abstract Introduction Chimeric antigen receptor (CAR)-T cell therapy has significantly advanced the treatment of relapsed/refractory mantle...
CLEC2A, a validated cancer-specific antigen, is an ideal candidate for immunotherapeutic targeting in KMT2A-rearranged AML
Abstract Through an expansive proteo-genomic screening of over 3000 AML samples and over 200 normal hematopoietic counterparts, we discovere...
Targeting DCAF5 restores p53 tumor suppressor function and exerts anti-leukemic effects in AML
Abstract Background: Acute myeloid leukemia (AML) remains a therapeutic challenge due to its genetic complexity and frequent resistance to c...
Incidence and characteristics of infections in patients with multiple myeloma treated with BCMA bispecific antibodies in British Columbia
Abstract Background: Bispecific T-cell engagers (bispecifics) targeting BCMA have improved outcomes in relapsed/refractory multiple myeloma...
Boosting anti-tumor immunity in NRAS;ASXL1-driven Acute Myeloid Leukemia through combined inhibition of MEK and HDACs.
Abstract Acute myeloid leukemia (AML) is a highly aggressive blood cancer with 5-year overall survival rates of ~30%. Its treatment outcome...
Racial disparities in health outcomes of patients with diffuse large B-cell lymphoma using real-world data
Abstract Background: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. However, significant racial d...
Initial performance of pirtobrutinib: Real-world outcomes among CLL patients after prior covalent-BTKi and BCL2i use
Abstract Background: Non-covalent Bruton's tyrosine kinase inhibitors (BTKi) are third-generation BTKis that utilize non...
A retrospective analysis of clinical and laboratory predictor of thrombosis and bleeding complications of patients on adult extracorporeal membrane oxygenation
Abstract INTRODUCTION There has been an increasing number of extracorporeal membrane oxygenation (ECMO) centers in the p...
Factor bb as a biomarker during breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria
Abstract Paroxysmal Nocturnal Hemoglobinuria (PNH) is a clonal disorder caused by loss of complement regulators on hematopoietic stem cells,...
Intravenously administered LV-169 delivers a functional BCMA-CAR transgene to niche-resident T cells and leads to elimination of disseminated myeloma in MHC-deficient NSG mice
Abstract Chimeric Antigen Receptor (CAR) T cell therapy is a transformative treatment for hematologic malignancies. However, ex vivo autolog...
Prophylactic tocilizumab in Relapsed/Refractory multiple myeloma patients treated with bispecific antibodies: A single centre experience
Abstract Background. Bispecific antibodies represent a novel valid therapeutic approach for heavily treated relapsed/refractory multiple mye...
Motixafortide + G-CSF hematopoietic stem cell mobilization in patients with multiple myeloma following quadruplet induction therapy
Abstract Quadruplet (quad) induction (anti-CD38 mAb, IMiD, PI and steroid) has become the standard-of-care (SoC) in transplant-eligible newl...
Who needs second-line therapy? predictors of sustained response in autoimmune hemolytic anemia
Abstract Background: Autoimmune hemolytic anemia (AIHA) is a rare, heterogeneous disorder characterized by premature erythrocyte destruction...
Pediatric idiopathic multicentric castleman disease is often severe and responds to siltuximab
Abstract Background: Idiopathic multicentric Castleman disease (iMCD) is a potentially fatal hematologic disorder marked by widespread lymph...
Insights into clonal and CBC changes at disease evolution among ccus patients
Abstract Background: Clonal cytopenia of undetermined significance (CCUS) is defined as clonal hematopoiesis in the absence of a hematologic...
Epigenetic priming improves survival for pediatric Acute Myeloid Leukemia: Results from the multicenter randomized AML16 trial
Abstract Genome-wide loss of DNA methylation accompanied by hypermethylation of promoter-associated CpG-islands is a hallmark of cancer. DNA...
Mechanistic role and prognostic value of CD20-positive microvesicles in rituximab-treated diffuse large B-cell lymphoma
Abstract Background The addition of rituximab, an anti-CD20 monoclonal antibody, to the R-CHOP (rituximab, cyclophospham...
Adoptive T-cell therapy targeting a novel non-canonical neoantigen derived from a translated AML1-ETO lncrna shows clinical activity in a first-in-human trial for t(8;21) AML
Abstract Background: Acute myeloid leukemia (AML) with the t(8;21)(q22;q22) translocation, a hallmark of core-binding factor AML (CBF-AML),...
Real-world overall survival and time to next treatment among elderly United States Medicare beneficiaries with chronic lymphocytic leukemia in the front-line setting
Abstract Background: Over the past decade, the chronic lymphocytic leukemia (CLL) treatment landscape has evolved with the approval of novel...
Impact of statin use on cardiovascular and hematologic outcomes among patients with myeloproliferative neoplasms
Abstract Introduction: Myeloproliferative neoplasms (MPNs), which include essential thrombocythemia (ET), polycythemia vera (PV), and myelof...
Myeloproliferative neoplasms-unclassifiable (MPN-U): A carefully curated series of 30 Mayo Clinic patients
Abstract Background Although myeloproliferative neoplasm-unclassifiable (MPN-U) stands as a distinct entity in the International Consensus C...
Hematological and inflammatory response trajectories in vexas syndrome patients treated with hypomethylating agents
Abstract Background: VEXAS (Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic) syndrome is a severe autoinflammatory syndrome frequen...
KIT mutant/core binding factor (CBF)-negative (CBF-Neg) AML might be an underestimated and distinct subgroup with poor prognosis: A single-center retrospective study
Abstract Background: KIT mutation, which was detected in 4%-6% de novo acute myeloid leukemia (AML), most frequently occurred in core bindin...
Anti-CD19 chimeric antigen receptor T-cell therapy for patients with non-Hodgkin's lymphoma and concurrent autoimmune disease
Abstract Introduction: CD19 targeted chimeric antigen receptor T cell therapy (CART) is standard of care (SOC) treatment (tx) for relapsed/r...
Thymopoiesis as a biomarker of cancer risk and outcome
Abstract T cells prevent cancer development and control its spread. Recent data showed that the thymus produces T cells late into adult life...